← All Sight Sciences, INC filings

Sight Sciences, INC 10-Q quarterly reports

Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.

NASDAQ
SGHT
Sight Sciences, INC
10-Q: Sight Sciences Reports Q3 Loss Narrows Amid Restructuring
Sight Sciences, Inc. reported a narrower net loss in Q3 2025, driven by significant operating expense reductions and workforce restructuring, despite an overall revenue decline.
NASDAQ
SGHT
Sight Sciences, INC
10-Q: Sight Sciences Q2 2025: Revenue Declines Amid Headwinds
Sight Sciences reported a significant revenue decline in Q2 2025, driven by reduced Surgical Glaucoma sales due to Medicare reimbursement changes and decreased Dry Eye demand following a price increase.
NASDAQ
SGHT
Sight Sciences, INC
10-Q: Sight Sciences Reports Q1 2025 Results: Revenue Declines Amid Reimbursement and Competitive Pressures
Sight Sciences' Q1 2025 revenue decreased by 9.1% year-over-year, primarily due to challenges in the Surgical Glaucoma segment and lower demand for Dry Eye products following a price increase.
NASDAQ
SGHT
Sight Sciences, INC
10-Q: Sight Sciences Reports Third Quarter 2024 Results, Navigates Reimbursement Changes
Sight Sciences reported its third quarter 2024 financial results, highlighting a slight increase in Surgical Glaucoma revenue and addressing the impact of new Medicare coverage policies.
NASDAQ
SGHT
Sight Sciences, INC
10-Q: Sight Sciences Reports Second Quarter 2024 Results, Revenue Declines Amid Strategic Shift
Sight Sciences reported a decrease in revenue for the second quarter of 2024, alongside a strategic realignment focused on long-term growth and profitability.
NASDAQ
SGHT
Sight Sciences, INC
10-Q: Sight Sciences Reports First Quarter 2024 Results, Revenue Growth Driven by Surgical Glaucoma Segment
Sight Sciences' first quarter 2024 results show a slight increase in overall revenue, primarily driven by growth in the Surgical Glaucoma segment, while the Dry Eye segment experienced a decline.